Compare HDL & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDL | CERT |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | Singapore | United States |
| Employees | 14003 | N/A |
| Industry | Restaurants | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.7M | 860.9M |
| IPO Year | N/A | 2020 |
| Metric | HDL | CERT |
|---|---|---|
| Price | $13.41 | $6.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 2.2K | ★ 2.5M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $14.73 | $4.18 |
| Revenue Next Year | $12.94 | $5.39 |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $13.31 | $5.19 |
| 52 Week High | $23.62 | $13.88 |
| Indicator | HDL | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 55.41 |
| Support Level | $13.31 | $5.93 |
| Resistance Level | $15.40 | $6.48 |
| Average True Range (ATR) | 0.24 | 0.28 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 4.59 | 76.87 |
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.